Pasithea Therapeutics Corp (KTTA)

Currency in USD
0.685
-0.005(-0.72%)
Closed·
After Hours
0.682-0.004(-0.51%)
·
KTTA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
KTTA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.6710.699
52 wk Range
0.6507.500
Key Statistics
Prev. Close
0.69
Open
0.69
Day's Range
0.671-0.699
52 wk Range
0.65-7.5
Volume
62.88K
Average Volume (3m)
937.59K
1-Year Change
-86.41%
Book Value / Share
4.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KTTA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Pasithea Therapeutics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Pasithea Therapeutics Corp Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company’s lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Compare KTTA to Peers and Sector

Metrics to compare
KTTA
Peers
Sector
Relationship
P/E Ratio
−0.4x−4.1x−0.5x
PEG Ratio
−0.010.010.00
Price/Book
0.4x2.8x2.6x
Price / LTM Sales
-153.9x3.3x
Upside (Analyst Target)
-172.0%43.5%
Fair Value Upside
Unlock−0.7%6.9%Unlock

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-1.61 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KTTA Income Statement

People Also Watch

7.4100
CYCC
-9.74%
430.37
MEDP
-1.36%
16.26
SRPT
-2.93%
13.0600
INKT
-10.12%
5.6600
BGLC
-1.22%

FAQ

What Stock Exchange Does Pasithea Therapeutics Trade On?

Pasithea Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Pasithea Therapeutics?

The stock symbol for Pasithea Therapeutics is "KTTA."

What Is the Pasithea Therapeutics Market Cap?

As of today, Pasithea Therapeutics market cap is 5.10M.

What Is Pasithea Therapeutics's Earnings Per Share (TTM)?

The Pasithea Therapeutics EPS (TTM) is -9.80.

From a Technical Analysis Perspective, Is KTTA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pasithea Therapeutics Stock Split?

Pasithea Therapeutics has split 1 times.

How Many Employees Does Pasithea Therapeutics Have?

Pasithea Therapeutics has 4 employees.

What is the current trading status of Pasithea Therapeutics (KTTA)?

As of 07 Aug 2025, Pasithea Therapeutics (KTTA) is trading at a price of 0.69, with a previous close of 0.69. The stock has fluctuated within a day range of 0.67 to 0.70, while its 52-week range spans from 0.65 to 7.50.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.